Drug
Orelabrutinib
Orelabrutinib: highest development phase Phase 3, developed by InnoCare Pharma, Zenas BioPharma (USA), LLC. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- InnoCare Pharma, Zenas BioPharma (USA), LLC
Trials
| Drug | Phase | Indication |
|---|---|---|
| Orelabrutinib NCT06004856 | Phase 3 | Chronic Primary Immune Thrombocytopenia (ITP) |
| Orelabrutinib NCT06082102 | Phase 3 | Relapsed/Refractory Marginal Zone Lymphoma |
| Orelabrutinib NCT06363994 | Phase 3 | Mantle Cell Lymphoma |
| Orelabrutinib NCT07067463 | Phase 3 | Multiple Sclerosis (MS) Primary Progressive |
| Orelabrutinib NCT04304040 | Phase 1/2 | B-cell Lymphoma Recurrent |
| Orelabrutinib NCT05284175 | Not Applicable | Neuromyelitis Optica Spectrum Disorder |
Latest
No recent events.
Follow Orelabrutinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.